Abstract
Sixteen adult subjects with asthma in a clinical steady state were studied. On day 1, after baseline spirometry, they underwent four histamine inhalation tests with functional recovery between each test. The provocative concentration causing a 20% fall in FEV 1 (PC 20) was obtained after each test. On days 2, 3, and 4, after baseline spirometry, active and placebo ascorbic acid (2 gm) was administered orally, double-blind, according to a 4.3.1 two-treatment crossover study design. One hour later, spirometry was performed, and PC 20 was reassessed. We found no significant changes in FEV 1 and FVC after ascorbic acid as compared with placebo administration. There was no difference between PC 20 on days 2, 3, and 4 and by standardizing for the four PC 20 results obtained on day 1. We conclude that ascorbic acid has no acute bronchodilator effect and does not alter bronchial responsiveness to histamine in subjects with asthma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
